Minimally Invasive Coronary Artery Bypass Supported by Cangrelor

Summary

The purpose of this study is to find out whether it is safe and practical to perform MIDCAB surgery (a minimally invasive heart bypass procedure) while patients receive a continuous cangrelor infusion during the operation. Cangrelor is a medicine that helps prevent blood clots and works quickly through a vein drip. The study compares patients receiving cangrelor during surgery to patients who had the same surgery in the past while on aspirin, with or without cangrelor given beforehand. Study Question: Can MIDCAB surgery be safely performed under cangrelor infusion, without increasing the risk of bleeding or other complications? Hypothesis: Using cangrelor during MIDCAB surgery is safe and feasible, and it provides effective protection against blood clots during the procedure. This study will help doctors understand whether intraoperative cangrelor can improve patient safety and outcomes in minimally invasive heart surgery.

Eligibility

Inclusion Criteria for the historical control arm:

* Age ≥18 years old
* CABG with IMA-LAD graft in MIDCAB technique

Inclusion criteria for the prospective arm:

* Age ≥18 years old
* CABG with IMA-LAD graft in MIDCAB technique
* Signed informed consent

Exclusion criteria for the historical control arm

* Administration of fibrinolytics or GP IIb/IIIa inhibitors
* Previous intracranial hemorrhage
* Known bleeding diathesis
* Patients undergoing concomitant PCI and MIDCAB
* Severe renal or liver disease
* Pregnancy or breast feeding

Exclusion criteria for the prospective arm

* Unconsciousness
* Known hypersensitivity to study drug (cangrelor)
* Recent administration of fibrinolytics or GP IIb/IIIa inhibitors
* Previous intracranial hemorrhage
* Known bleeding diathesis
* Patients undergoing concomitant PCI and MIDCAB
* Severe renal or liver disease
* Pregnancy or breast feeding

Conditions4

Browse More Trials